CVRx, Inc.
HealthcareNASDAQ:CVRX · NASDAQ Global Select
+$0.14 today
Vol 0.22M · Avg 0.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-135.6%
avg -47.4%
ROIC
-56.0%
avg -38.4%
ROA
-50.9%
avg -37.9%
Analysis
ROA is currently the strongest return metric at -50.9% versus its period average of -37.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin Hykes | President, Chief Executive Officer & Director | $2.64M | — | 60 | $11,182.00 | 0.04% |
Philip Adamson | Chief Medical Officer | $1.10M | — | 65 | $61,578.00 | 0.23% |
Robert Allen John | Chief Revenue Officer | $1.05M | — | 52 | $86,036.00 | 0.32% |
Paul Verrastro | Chief Marketing & Strategy Officer | $598,972.00 | — | 63 | $60,551.00 | 0.23% |
Jared Oasheim | Chief Financial Officer | $517,269.00 | — | 43 | $96,703.00 | 0.36% |
Brent Binkowski | Chief Operating Officer | — | — | 57 | $31,600.00 | 0.12% |
Gregory Morrison | Chief Human Resources Officer | — | — | 62 | $154,500.00 | 0.58% |
Bonnie Handke | Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics | — | — | — | — | — |
Jonelle R. Burnham | Vice President & General Counsel | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$300,376.86
Sells
13
$987,617.05
Net Sentiment
$687,240.19
Net selling
Most Active
JOHNSON & JOHNSON
8 transactions
1–10 of 15
Analysis
Insiders reported 2 buys worth $300,376.86 and 13 sells worth $987,617.05 over the last 12 months. That adds up to net selling of $687,240.19. JOHNSON & JOHNSON was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +86.5% | +19.1% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +86.5% over three years. Forward estimates point to Revenue at +19.1% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cerus Corporation
NASDAQ:CERS
$512.94M
Viemed Healthcare, Inc.
NASDAQ:VMD
$400.62M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Owens & Minor, Inc.
OMI
$207.07M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Who manages CVRX?
CVRx, Inc. (CVRX) lists 9 active executives. The top listed executive is Philip Adamson, Chief Medical Officer.
Are CVRX insiders buying or selling?
Recent insider activity shows net buying of $29.64M.
Explore More
Continue the stock analysis
Jump to another research area for this company.